Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 90

Results For "iron"

901 News Found

Merck brings new renewable energy to the grid through VPPA with Enel Green Power
News | March 18, 2021

Merck brings new renewable energy to the grid through VPPA with Enel Green Power

Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power


LifeClean and Lonza Specialty Ingredients sign distribution agreement for disinfectants
News | March 17, 2021

LifeClean and Lonza Specialty Ingredients sign distribution agreement for disinfectants

Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.


Merck FY20 sales up 8.6% euro 17.5 bn
News | March 04, 2021

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.


Accelerated growth in pharma depends on the right policies: Experts
News | March 01, 2021

Accelerated growth in pharma depends on the right policies: Experts

A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders


Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
News | February 11, 2021

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda

The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.


Zydus completes enrolment for two Phase Ill trials of Desidustat
News | February 08, 2021

Zydus completes enrolment for two Phase Ill trials of Desidustat

The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.


Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
News | January 23, 2021

Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr

EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.


Vaishali Pharma bags order worth Rs. 32 Cr
News | January 14, 2021

Vaishali Pharma bags order worth Rs. 32 Cr

The company is expecting tremendous growth and a better quarterly performance


Commercial disinfectants equally as effective against new COVID strains: CBC
News | January 13, 2021

Commercial disinfectants equally as effective against new COVID strains: CBC

Viruses evolve into new strains when there is a change to their genetic composition.